A role for PPARβ/δ in ocular angiogenesis

PPAR Research

Volumn , Issue , 2008, Pages

  Bishop Bailey, David ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; RETINOIC ACID; VASCULOTROPIN;

ANGIOGENESIS; BLOOD CLOTTING; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; ENDOTHELIUM CELL; EYE DEVELOPMENT; EYE DISEASE; HUMAN; INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION;

EID: 43949123846     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/825970     Document Type: Review

References (58)

1. Moraes L. A., Piqueras L., Bishop-Bailey D.
2. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., Wahli W., Control of the peroxisomal β -oxidation pathway by a novel family of nuclear hormone receptors Cell 1992 68 5 879 887
3. Kliewer S. A., Forman B. M., Blumberg B., Differential expression and activation of a family of murine peroxisome proliferator-activated receptors Proceedings of the National Academy of Sciences of the United States of America 1994 91 15 7355 7359
4. Mukherjee R.
5. Vosper H., Patel L., Graham T. L., The peroxisome proliferator-activated receptor δ promotes lipid accumulation in human macrophages Journal of Biological Chemistry 2001 276 47 44258 44265
6. Barak Y., Liao D., He W., Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer Proceedings of the National Academy of Sciences of the United States of America 2002 99 1 303 308
7. Michalik L., Desvergne B., Tan N. S., Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR) α and PPAR β mutant mice Journal of Cell Biology 2001 154 4 799 814
8. Bishop-Bailey D.
9. Michalik L., Auwerx J., Berger J. P., International union of pharmacology. LXI. Peroxisome proliferator-activated receptors Pharmacological Reviews 2006 58 4 726 741
10. Forman B. M., Chen J., Evans R. M., Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ Proceedings of the National Academy of Sciences of the United States of America 1997 94 9 4312 4317
11. Lee C.-H., Kang K., Mehl I. R., Peroxisome proliferator-activated receptor δ promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage Proceedings of the National Academy of Sciences of the United States of America 2006 103 7 2434 2439
12. Ghosh M., Wang H., Ai Y., COX-2 suppresses tissue factor expression via endocannabinoid-directed PPAR δ activation Journal of Experimental Medicine 2007 204 9 2053 2061
13. Shaw N., Elholm M., Noy N.
14. Luo T., Sakai Y., Wagner E., Dräger U. C.
15. Ziouzenkova O., Orasanu G., Sharlach M., Retinaldehyde represses adipogenesis and diet-induced obesity Nature Medicine 2007 13 6 695 702
16. Desvergne B.
17. Mark M., Ghyselinck N. B., Chambon P.
18. Folkman J.
19. Bishop-Bailey D., Hla T.
20. Panigrahy D., Singer S., Shen L. Q., PPAR γ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis Journal of Clinical Investigation 2002 110 7 923 932
21. Murata T., He S., Hangai M., Peroxisome proliferator-activated receptor- γ ligands inhibit choroidal neovascularization Investigative Ophthalmology & Visual Science 2000 41 8 2309 2317
22. Hatae T., Wada M., Yokoyama C., Shimonishi M., Tanabe T.
23. Stephen R. L., Gustafsson M. C. U., Jarvis M., Activation of peroxisome proliferator-activated receptor δ stimulates the proliferation of human breast and prostate cancer cell lines Cancer Research 2004 64 9 3162 3170
24. Piqueras L., Reynolds A. R., Hodivala-Dilke K. M., Activation of PPAR β/δ induces endothelial cell proliferation and angiogenesis Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 1 63 69
25. Liou J.-Y., Lee S., Ghelani D., Matijevic-Aleksic N., Wu K. K.
26. Wilker E., Yaffe M. B.
27. Pola R.
28. Saito A., Sugawara A.
29. Bradley J., Ju M., Robinson G. S.
30. Hoeben A., Landuyt B.
31. Müller-Brüsselbach S., Kömhoff M., Rieck M., Deregulation of tumor angiogenesis and blockade of tumor growth in PPAR β -deficient mice The EMBO Journal 2007 26 15 3686 3698
32. Abdollahi A.
33. Febbraio M., Hajjar D. P., Silverstein R. L., CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism Journal of Clinical Investigation 2001 108 6 785 791
34. Mwaikambo B. R., Sennlaub F., Ong H., Chemtob S., Hardy P.
35. Adamkiewicz J., Kaddatz K., Rieck M., Wilke B., Müller- Brüsselbach S., Müller R.
36. Bohman S., Matsumoto T., Suh K., Proteomic analysis of vascular endothelial growth factor-induced endothelial cell differentiation reveals a role for chloride intracellular channel 4 (CLIC4) in tubular morphogenesis Journal of Biological Chemistry 2005 280 51 42397 42404
37. Kuppumbatti Y. S., Rexer B., Nakajo S., Nakaya K., Mira-y-Lopez R., CRBP suppresses breast cancer cell survival and anchorage-independent growth Oncogene 2001 20 50 7413 7419
38. Kontos C. D., Stauffer T. P., Yang W.-P., Tyrosine 1101 of Tie2 is the major site of association of p85 and is required for activation of phosphatidylinositol 3-kinase and Akt Molecular and Cellular Biology 1998 18 7 4131 4140
39. Fauconnet S., Lascombe I., Chabannes E., Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator- activated receptors in bladder cancer cells Journal of Biological Chemistry 2002 277 26 23534 23543
40. Hollingshead H. E., Killins R. L., Borland M. G., Peroxisome proliferator-activated receptor- β/δ (PPAR β/δ) ligands do not potentiate growth of human cancer cell lines Carcinogenesis 2007 28 12 2641 2649
41. Wang D., Wang H., Guo Y., Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression Proceedings of the National Academy of Sciences of the United States of America 2006 103 50 19069 19074
42. Higashiyama H., Billin A. N., Okamoto Y., Kinoshita M., Asano S.
43. Campochiaro P. A.
44. Fruttiger M.
45. Chen J., Smith L. E. H.
46. Starita C., Patel M., Katz B., Adamis A. P., Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen®) in diabetic retinopathy Developments in Ophthalmology 2007 39 122 148
47. Shojaei F., Ferrara N.
48. Schmidt-Erfurth U. M.
49. Adamis A. P.
50. Takeda A. L.
51. Ishida S., Usui T., Yamashiro K., VEGF 164 -mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization Journal of Experimental Medicine 2003 198 3 483 489
52. Usui T., Ishida S., Yamashiro K., VEGF 164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2 Investigative Ophthalmology & Visual Science 2004 45 2 368 374
53. Yoshida S.
54. Rak J.
55. Grossniklaus H. E.
56. Ali F. Y., Davidson S. J., Moraes L. A., Role of nuclear receptor signaling in platelets: antithrombotic effects of PPAR β The FASEB Journal 2006 20 2 326 328
57. Rival Y.
58. Lee C.-H., Chawla A., Urbiztondo N., Liao D., Boisvert W. A., Evans R. M.